Evaluation of the efficacy of Conbercept in the treatment of diabetic macular edema based on OCTA

Ba, Teer; Zhou, Lili; Zhang, Han; Zhang, Xiaoguang; Guo, Shixuan; Li, Huixia; Tian, Haiyan; Caihan, Qiqige; Bai, Gang; Zhou, Jing; Qi, Lao; Zhang, Xueyan; Zhang, Guisen

doi:10.1097/md.0000000000021992

Cited by 7 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 9 , 10 No capillary perfusion, tissue inflammation, ischemia and hypoxia can increase vascular permeability and further aggravate macular edema, and long-term diffuse macular edema can cause severe visual damage. 11 , 12 Moreover, the treatment method of CRVO combined with macular edema is limited, and the efficacy is poor, which seriously affects the physical and mental health of patients. 13 Therefore, it is urgent to explore relevant biological evaluation indexes for early detection and timely treatment in clinic, so as to improve the prognosis of patients with CRVO combined with macular edema.…”

Section: Discussionmentioning

confidence: 99%

Expressions of HIF-1α and MiR-210 in aqueous humor of patients with central retinal vein occlusion combined with macular edema

Hu¹,

Liu²,

Sun³

et al. 2022

Pak J Med Sci

View full text Add to dashboard Cite

Objectives: To detect the expressions of hypoxia-inducible factor 1α (HIF-1α) and microRNA-210 (miR-210) in the aqueous humor of patients with central retinal vein occlusion (CRVO) combined with macular edema, and explore their correlations with CRVO combined with macular edema. Methods: A total of 65 patients (65 eyes) with CRVO combined with macular edema who were treated in the Lixiang Eye Hospital of Soochow University from April 2018 to March 2020 were selected as subjects (CRVO combined with macular edema group). Additionally, 74 patients (74 eyes) with cataract were selected during the same period as cataract control group. The expressions of HIF-1α mRNA and miR-210 in the aqueous humor were detected by quantitative real-time PCR (qRT-PCR). The levels of monocyte chemoattractant protein-1 (MCP-1), interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF) in the aqueous humor were measured using enzyme-linked immunosorbent assay (ELISA). The correlations of HIF-1α mRNA and miR-210 in the aqueous humor of patients with CRVO combined with macular edema with vasoactive molecule levels, the diagnostic value of HIF-1α mRNA and miR-210 levels in the aqueous humor in CRVO combined with macular edema, as well as the factors influencing the occurrence of CRVO combined with macular edema were analyzed. Results: The levels of HIF-1α mRNA, miR-210, MCP-1, VEGF and IL-6 in the aqueous humor of the CRVO combined with macular edema group were higher than those of the cataract control group (P < 0.05). In the CRVO combined with macular edema group, HIF-1α mRNA and miR-210 levels in the aqueous humor were positively correlated (r = 0.522, P < 0.05), and they were positively correlated with MCP-1, VEGF and IL-6 levels (P < 0.05). The area under the curve (AUC) of HIF-1α mRNA and miR-210 in the aqueous humor in diagnosing CRVO combined with macular edema was 0.888 and 0.866, the specificity was 95.9% and 85.1%, and the sensitivity was 76.9% and 80.0%, respectively. The AUC of their combination was 0.937, with the specificity of 93.2% and the sensitivity of 86.2%. HIF-1α, miR-210 and VEGF were the independent risk factors affecting the occurrence of CRVO combined with macular edema (P < 0.05). Conclusion: In patients with CRVO combined with macular edema, HIF-1α mRNA and miR-210 were highly expressed in the aqueous humor, which may play an important role in the occurrence and development of the disease. doi: https://doi.org/10.12669/pjms.38.5.5092 How to cite this:Hu P, Liu G, Sun H, Wei W. Expressions of HIF-1α and MiR-210 in aqueous humor of patients with central retinal vein occlusion combined with macular edema. Pak J Med Sci. 2022;38(5):---------. doi: https://doi.org/10.12669/pjms.38.5.5092 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

Section: Discussionmentioning

confidence: 99%

Expressions of HIF-1α and MiR-210 in aqueous humor of patients with central retinal vein occlusion combined with macular edema

Hu¹,

Liu²,

Sun³

et al. 2022

Pak J Med Sci

View full text Add to dashboard Cite

show abstract

“…The evidence from retrospective studies have shown that 3-monthly loading-dose intravitreal injections of Conbercept as well as pro re nata (PRN) treatment were efficacious in treating DME [50,69,70]. An ongoing multicenter, randomized, single-masked clinical trial will be the first to evaluate the safety and the therapeutic effect of 6 + PRN vs. 3 + PRN regimen in patients with DMO [71]. This could allow for a development of a better treatment strategy.…”

Section: Ocular Treatment Of Diabetic Retinal Diseasesmentioning

confidence: 99%

Recent Advancements in the Medical Treatment of Diabetic Retinal Disease

Szymańska

Mahmood

Yap

et al. 2021

IJMS

View full text Add to dashboard Cite

Diabetic retinal disease remains one of the most common complications of diabetes mellitus (DM) and a leading cause of preventable blindness. The mainstay of management involves glycemic control, intravitreal, and laser therapy. However, intravitreal therapy commonly requires frequent hospital visits and some patients fail to achieve a significant improvement in vision. Novel and long-acting therapies targeting a range of pathways are warranted, while evidence to support optimal combinations of treatments is currently insufficient. Improved understanding of the molecular pathways involved in pathogenesis is driving the development of therapeutic agents not only targeting visible microvascular disease and metabolic derangements, but also inflammation and accelerated retinal neurodegeneration. This review summarizes the current and emerging treatments of diabetic retinal diseases and provides an insight into the future of managing this important condition.

show abstract

“…It has been widely utilized in clinical settings (5)(6)(7). Research has substantiated the effectiveness of conbercept in managing DME (8,9) and PDR (10,11). Initial reports of DRSS score improvements postanti-VEGF injections emerged from clinical trials focusing on DME.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of intravitreal injection of conbercept for moderate to severe nonproliferative diabetic retinopathy

Shen,

Zheng,

Gao

et al. 2024

Front. Med.

View full text Add to dashboard Cite

PurposeThis study aimed to assess the effectiveness and safety of intravitreal injection of conbercept (IVC) in treating moderate to severe nonproliferative diabetic retinopathy (NPDR), with or without accompanying diabetic macular edema.MethodsIn this longitudinal retrospective study, 35 patients (50 eyes) with moderate to severe NPDR and Diabetic Retinopathy Severity Scale (DRSS) scores between 43 and 53 were treated at the Department of Ophthalmology, First Affiliated Hospital of Kunming Medical University, from October 2018 to January 2023. Treatment protocol included three monthly IVC injections followed by a pro re nata (PRN) regimen over a two-year follow-up period. Outcome measures were best-corrected visual acuity (BCVA), intraocular pressure, central macular thickness (CMT), extent of hard exudate (HE), and changes in DRSS scores. DRSS scores before and after treatment were analyzed using the Wilcoxon rank-sum test. Both systemic and ocular adverse events were meticulously documented to ascertain safety.ResultsFrom baseline to the final follow-up, the mean BCVA improved from 0.41 ± 0.39 to 0.23 ± 0.20 logMAR (p<0.05). The mean CMT decreased from 306.22 ± 77.40 to 297.97 ± 88.15 μm (p = 0.385). At 24 months, DRSS scores improved by ≥1 stage in 40 eyes (80%), ≥ 2 stages in 28 eyes (56%), ≥3 stages in 10 eyes (20%), and remained stable in 6 eyes (12%). The DRSS scores at each follow-up interval demonstrated statistically significant improvement from baseline (p<0.05). In 15 of 27 eyes (55.56%) with diabetic macular edema (DME), there was a significant reduction in the mean area of HE from baseline (p<0.05). No serious systemic adverse events were observed.ConclusionIVC is an effective and safe treatment for moderate to severe NPDR, demonstrating significant improvements in DRSS scores.

show abstract

Evaluation of the efficacy of Conbercept in the treatment of diabetic macular edema based on OCTA

Cited by 7 publications

References 10 publications

Expressions of HIF-1α and MiR-210 in aqueous humor of patients with central retinal vein occlusion combined with macular edema

Expressions of HIF-1α and MiR-210 in aqueous humor of patients with central retinal vein occlusion combined with macular edema

Recent Advancements in the Medical Treatment of Diabetic Retinal Disease

Efficacy and safety of intravitreal injection of conbercept for moderate to severe nonproliferative diabetic retinopathy

Contact Info

Product

Resources

About